Paridiprubart (NI-0101) is a humanised anti-TLR4 monoclonal antibody. Paridiprubart has the potential for the research of rheumatoid arthritis.
References:
[1]. Monnet E, et al. Efficacy and safety of NI-0101, an anti-toll-like receptor 4 monoclonal antibody, in patients with rheumatoid arthritis after inadequate response to methotrexate: a phase II study. Ann Rheum Dis. 2020 Mar;79(3):316-323.
















